FDA has lifted a ban on continuing clinical trials of an injectable form of lenacapavir for the treatment and prevention of HIV. Previously, the agency had banned further trials due to the negative impact of borosilicate vials on the drug. Now aluminosilicate glass containers will be used to store the drug.